ReviewCNS oncology2013
Medulloblastoma: recurrence and metastasis.
Review in CNS oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial.Pediatric blood & cancer · 2021Trial
- Significance of Early Proton Beam Therapy Initiation in Achieving Complete Response in Pediatric Medulloblastoma: A Retrospective Study.Cancer medicine · 2026Article
- Treatment strategies for relapsed medulloblastoma in the pediatric population: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Simvastatin suppresses spinal cord metastasis of medulloblastoma at clinically significant doses.Cell death & disease · 2025Article
- Medulloblastoma: biology and immunotherapy.Frontiers in immunology · 2025Review
- Cytokine profile of cerebrospinal fluid in pediatric patients with metastatic medulloblastoma.Heliyon · 2024Article
- Pediatric-Like Brain Tumors in Adults.Advances and technical standards in neurosurgery · 2024Review
- Article
- Molecular characterization of sub-frontal recurrent medulloblastomas reveals potential clinical relevance.Frontiers in neurology · 2023Article
- Production of a SCID mouse model of medulloblastoma to explore the therapeutic value of targeting tumor driver genes.Experimental and therapeutic medicine · 2021Article
- Brain tumors: Cancer stem-like cells interact with tumor microenvironment.World journal of stem cells · 2020Review
- Article
- Heme Oxygenase-1 in Central Nervous System Malignancies.Journal of clinical medicine · 2020Review
- Necroptotic astrocytes contribute to maintaining stemness of disseminated medulloblastoma through CCL2 secretion.Neuro-oncology · 2020Article
- Heat Shock Cognate Protein 70 Enhanced Integrin β1 Mediated Invasion in Cancer Cells.Cancer management and research · 2020Article
- [Risk factors for recurrence within 2 years in children with medulloblastoma].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2019Article
- TRIM59 induces epithelial-to-mesenchymal transition and promotes migration and invasion by PI3K/AKT signaling pathway in medulloblastoma.Oncology letters · 2018Article
- MicroRNA-206 inhibits the viability and migration of medulloblastoma cells by targeting LIM and SH3 protein 1.Experimental and therapeutic medicine · 2017Article
- ATOH1 Promotes Leptomeningeal Dissemination and Metastasis of Sonic Hedgehog Subgroup Medulloblastomas.Cancer research · 2017Article
- IL-17 promoted the inhibition of medulloblastoma in mice by splenocyte injection.European journal of medical research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Medulloblastoma is the most common malignant brain tumor of childhood. Although there is now long-term survival or cure for the majority of children, the survivors bear a significant burden of complications due, at least in part, to the intense therapies given to ensure eradication of the tumor. Significant efforts have been made over the years to be able to distinguish between patients who do and do not need intensive therapies. This review summarizes the history and current state of clinical risk stratification, pathologic diagnosis and genetics. Recent developments in correlation between genetics and pathology, genome-wide association studies and the biology of medulloblastoma metastasis are discussed in detail. The current state of clinical treatment trials are reviewed and placed into the perspective of potential novel therapies in the near term.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.